Macrophages and Therapeutic Resistance in Cancer

Slides:



Advertisements
Similar presentations
Arne R. M. van der Bilt, Elisabeth G. E
Advertisements

Kusumawadee Utispan, Sittichai Koontongkaew 
Chemotherapy and Cancer Stem Cells
“Toll”-erance in the Skin
A Novel Link between Inflammation and Cancer
Volume 7, Issue 3, Pages (March 2005)
Settling a Nervous Stomach: The Neural Regulation of Enteric Cancer
Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis
CD5: A New Partner for IL-6
Intravascular Survival and Extravasation of Tumor Cells
Cancer Immunotherapy by Dendritic Cells
S. S. Pullamsetti, R. Savai, W. Janssen, B. K. Dahal, W. Seeger, F
Oncology Meets Immunology: The Cancer-Immunity Cycle
Esther Bridges, Adrian L. Harris  Cancer Cell 
The Multifaceted Role of Perivascular Macrophages in Tumors
Volume 26, Issue 5, Pages (November 2014)
Multiple Effects of Angiopoietin-2 Blockade on Tumors
Some DCs Are “B”etter Immunity
Agonizing Integrin Antagonists?
Tailor-Made Renal Cell Carcinoma Vaccines
Tipping the Balancing ACT
Justin D. Lathia, John M. Heddleston, Monica Venere, Jeremy N. Rich 
Volume 26, Issue 1, Pages 1-2 (July 2014)
Metastasis-Promoting Immunity: When T Cells Turn to the Dark Side
Stealing VEGF from Thy Neighbor
Laurence Zitvogel, Guido Kroemer  Cancer Cell 
Macrophages and Therapeutic Resistance in Cancer
Bhagelu Ram Achyut, Li Yang  Gastroenterology 
The Microenvironmental Landscape of Brain Tumors
A TeNaCious Foundation for the Metastatic Niche
Metabolic Reprogramming of Immune Cells in Cancer Progression
Guardians of the Gut: Newly Appreciated Role of Epithelial Toll-Like Receptors in Protecting the Intestine  Matam Vijay-Kumar, Andrew T. Gewirtz  Gastroenterology 
Toll-like Receptor 9: AEP Takes Control
Mechanisms of Vessel Pruning and Regression
Interleukin-33 in Tissue Homeostasis, Injury, and Inflammation
Volume 26, Issue 5, Pages (November 2014)
Dietmar M.W. Zaiss, William C. Gause, Lisa C. Osborne, David Artis 
Pro-endometriotic niche in endometriosis
Macrophage Regulation of Tumor Responses to Anticancer Therapies
Yasmine Belkaid, Guillaume Oldenhove  Immunity 
Tumor Promotion via Injury- and Death-Induced Inflammation
Frances Balkwill, Kellie A. Charles, Alberto Mantovani  Cancer Cell 
Learning from PD-1 Resistance: New Combination Strategies
Tumor-Associated Macrophages: From Mechanisms to Therapy
Duality of the Immune Response in Cancer: Lessons Learned from Skin
Vicki Plaks, Niwen Kong, Zena Werb  Cell Stem Cell 
Wenjun Ouyang, Anne O’Garra  Immunity 
Multiple Effects of Angiopoietin-2 Blockade on Tumors
Azucena Ramos, Michael T. Hemann  Cell 
Azucena Ramos, Michael T. Hemann  Cell 
Macrophage Diversity Enhances Tumor Progression and Metastasis
Volume 22, Issue 2, Pages (August 2012)
Fibronectin at Select Sites Binds Multiple Growth Factors and Enhances their Activity: Expansion of the Collaborative ECM-GF Paradigm  Jia Zhu, Richard.
Inflammation, ROS, and Mutagenesis
The VEGF Family, the Inside Story
Macrophage Regulation of Tumor Responses to Anticancer Therapies
Pancreatic Cancer: Planning Ahead for Metastatic Spread
Andy J. Minn, E. John Wherry  Cell 
The Duality of Angiogenesis: Implications for Therapy of Human Disease
Learning from PD-1 Resistance: New Combination Strategies
Polarization of Tumor-Associated Macrophages: A Novel Strategy for Vascular Normalization and Antitumor Immunity  Yuhui Huang, Matija Snuderl, Rakesh.
Mesenchymal Stromal Cells: Sensors and Switchers of Inflammation
Releasing the Brakes on Cancer Immunotherapy
Mesenchymal Stromal Cells: New Directions
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Plasmacytoid Dendritic Cells in Melanoma: Can We Revert Bad into Good?
Some DCs Are “B”etter Immunity
At 17, In-10's Passion Need Not Inflame
Dietmar M.W. Zaiss, William C. Gause, Lisa C. Osborne, David Artis 
Something in the Air: Hyperoxic Conditioning of the Tumor Microenvironment for Enhanced Immunotherapy  Robert D. Leone, Maureen R. Horton, Jonathan D.
Presentation transcript:

Macrophages and Therapeutic Resistance in Cancer Brian Ruffell, Lisa M. Coussens  Cancer Cell  Volume 27, Issue 4, Pages 462-472 (April 2015) DOI: 10.1016/j.ccell.2015.02.015 Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 1 Clinical Implications of Macrophage Density Organs where tumor progression and/or clinical outcome are negatively associated with increased macrophage density are shown in red. Green indicates a positive association. Organs where the implications of macrophages density are unclear or unknown are shown in gray and black, respectively. Image created by Tarot Walker. Cancer Cell 2015 27, 462-472DOI: (10.1016/j.ccell.2015.02.015) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 2 Macrophage Polarization as a Dynamic System The integration of multiple signals emanating from the tumor microenvironment (outer circle) dictates the functional role of macrophages (inner circle). Integrins and toll-like receptors (TLRs) will be engaged by multiple ligands. Cancer Cell 2015 27, 462-472DOI: (10.1016/j.ccell.2015.02.015) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 3 Macrophage Function in the Tumor Microenvironment (A) Macrophage expression of IL-6 and TNF-α promotes survival signaling in neoplastic cells and resistance to chemotherapy and targeted agents. The expression of survival factors is dependent upon the protease activity of cathepsin B and/or S. (B) Neoplastic cell invasion of ectopic tissue can be promoted through the directed release of cytokines/chemokines such as epidermal growth factor (EGF) and CCL18 or through protease-dependent extracellular matrix (ECM) remodeling that may directly affect neoplastic migration or increase chemoattractant bioavailability. EGF expression is driven by signaling through the CSF-1R via neoplastic cell production of CSF-1 as well as T cell-derived IL-4 (not shown). (C) Macrophages directly promote angiogenesis via production of VEGFA and other angiogenic factors and can enhance VEGFA expression by endothelial cells through WNT7B. A subset of macrophages expressing the Tie2 receptor is recruited to the vasculature by mural cell/pericyte expression of ANG2 and is important in regulating vascular structure. (D) Direct suppression of a cytotoxic T cell (CTL) response can occur via expression of B7 family ligands (PD-L1, B7-H4). Indirect suppression may occur through release of IL-10 or recruitment of IL-10-expressing TRegs via CCL22, whereby IL-10 suppresses the capacity of dendritic cells to produce IL-12 and promote a TH1/CTL anti-tumor immune response. Cancer Cell 2015 27, 462-472DOI: (10.1016/j.ccell.2015.02.015) Copyright © 2015 Elsevier Inc. Terms and Conditions